Spero Therapeutics, Inc. entered into an Open Market Sale Agreement with Jefferies LLC on August 28, 2026, establishing a new at-the-market equity offering program allowing the sale of up to $100 million in common stock. Concurrently, the company terminated its prior Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co., which had authorized up to $75 million in sales but resulted in zero shares sold through that channel. Jefferies will act as sales agent for a commission of up to 3.0% of gross proceeds. Spero Therapeutics, Inc. operates in the biopharmaceutical industry, focusing on the development and commercialization of treatments for infectious diseases.
